CVE-2019-25716: Dräger Patient Monitor Denial-of-Service Vulnerability

Technical summary

CVE-2019-25716 is a denial-of-service vulnerability (CWE-15: External Control of Critical System Resource) affecting Dräger patient monitors. The flaw allows an unauthenticated attacker with network adjacency (AV:A) to send malformed packets that trigger uncontrolled device reboots. Repeated exploitation causes the monitor to cycle through restarts, lose its network configuration, and fall back to factory defaults. The CVSS 3.1 score of 6.5 (MEDIUM) reflects high availability impact with no confidentiality or integrity compromise. The attack requires no user interaction and succeeds under standard network conditions (AC:L).

Business impact

In clinical environments, continuous patient monitoring is critical for detecting deterioration and guiding care decisions. This vulnerability enables disruption of that surveillance capability—potentially delaying detection of cardiac events, respiratory distress, or other life-threatening changes. Repeated reboots force staff to reconfigure devices, divert clinical attention, and may necessitate fallback to manual observation or alternative monitoring methods. For hospital operations teams, the vulnerability introduces unplanned downtime and configuration drift that compounds troubleshooting burden during already-stressful clinical scenarios.

Affected systems

Three Dräger patient monitor product lines are affected: Infinity Delta, Delta XL, and Kappa. Both the monitor hardware and associated firmware versions are listed as vulnerable. Organizations should verify their specific firmware revisions against Dräger's official advisory to confirm exposure. The vulnerability requires the affected device to be connected to a network and reachable from an adjacent network segment.

Exploitability

Exploitation is straightforward from a technical perspective: an attacker needs only network adjacency (same subnet or accessible layer-2/3 segment) and the ability to craft and transmit raw network packets—no authentication, credential guessing, or social engineering required. The attack is reliable and repeatable. However, real-world deployment context matters: if monitors are isolated on a trusted clinical LAN with strict access controls, risk is substantially lower than in open network architectures. The vulnerability is not known to be exploited in active campaigns (KEV status: not listed).

Remediation

Contact Dräger for patched firmware versions specific to your monitor model and current firmware baseline. Verify patch availability through Dräger's security advisory and validate compatibility with your clinical IT environment before deployment. Test patches in a non-critical environment if possible. Interim mitigation includes network segmentation to restrict monitor access to trusted clinical workstations and staff, disabling unnecessary network services on the monitors, and enabling any available network access controls or firewall rules at the edge.

Patch guidance

Obtain the vendor advisory directly from Dräger to identify the patched firmware version applicable to your Infinity Delta, Delta XL, or Kappa devices and current firmware level. Coordinate with your biomedical engineering team and clinical IT leadership to schedule firmware updates during low-risk windows, ensuring rollback procedures are documented. Confirm that the patched firmware does not introduce new issues by reviewing Dräger's release notes and considering a staged rollout across your fleet. After patching, verify that the devices reconnect to your network and restore intended configuration automatically.

Detection guidance

Monitor for unexpected reboots or state changes on affected Dräger monitors using SNMP traps, syslog forwarding, or clinical engineering dashboards if available. Implement network-based detection by looking for malformed or suspicious packets destined to monitor IP addresses on the clinical network segment. Consider deploying a network TAP or span port to capture traffic to and from monitors for forensic review if suspicious activity is suspected. Clinical staff should be trained to report devices that cycle through boot loops or lose connectivity, as this is the visible symptom of active exploitation.

Why prioritize this

Although the CVSS score is MEDIUM and exploitation is network-adjacent, the clinical context elevates priority: patient monitors are safety-critical devices, and availability disruption directly impacts care quality. The attack is easy to execute and repeatable, making it suitable for low-skill adversaries or disgruntled insiders. Organizations should prioritize patching over time but should not deprioritize in favor of IT-only vulnerabilities. The lack of KEV listing suggests this is not yet a widespread attack vector, creating a window for proactive remediation.

Risk score, explained

The CVSS 3.1 score of 6.5 (MEDIUM, AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H) reflects a high-availability impact with limited scope (single device affected, not cascading). The attack vector being adjacent (not network-wide) and requiring no privileges or user interaction keeps the score moderate. In the specific context of medical devices in a healthcare facility, the business and safety implications warrant treating this as higher priority than a generic MEDIUM score might suggest.

Frequently asked questions